drugset / Trial / NCT01119963

Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

NCT01119963

Phase 2/3 Completed 152 enrolled Obstetrix Medical Group
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objective of the study is to determine if a weekly dose of 17 hydroxyprogesterone caproate (17P, Makena®) given to women with preterm rupture of the membranes will: 1. increase the probability of continuing the pregnancy until a favorable gestational age. 2. increase the interval between randomization and delivery. 3. decrease neonatal morbidity.

Timeline

Start
2011-10
Primary completion
2014-04
Completion
2014-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator 17-alpha-hydroxyprogesterone caproate Unknown 250 mg Intramuscular